Barclays PLC Takes $90,000 Position in Rockwell Medical, Inc. (NASDAQ:RMTI)

Barclays PLC bought a new stake in Rockwell Medical, Inc. (NASDAQ:RMTI) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,625 shares of the company’s stock, valued at approximately $90,000. Barclays PLC owned about 0.07% of Rockwell Medical at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in RMTI. Concurrent Investment Advisors LLC purchased a new stake in shares of Rockwell Medical in the third quarter valued at about $40,000. Verus Capital Partners LLC purchased a new stake in shares of Rockwell Medical in the third quarter valued at about $51,000. Beacon Financial Advisory LLC purchased a new stake in Rockwell Medical during the third quarter worth about $98,000. XTX Topco Ltd increased its holdings in Rockwell Medical by 45.7% during the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after buying an additional 8,922 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Rockwell Medical by 877.1% during the second quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock worth $181,000 after buying an additional 92,189 shares during the last quarter. Hedge funds and other institutional investors own 23.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Rodman & Renshaw assumed coverage on shares of Rockwell Medical in a research report on Thursday, November 14th. They set a “buy” rating and a $5.00 target price for the company. StockNews.com lowered shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Friday, December 20th. RODMAN&RENSHAW upgraded shares of Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Rockwell Medical in a research report on Monday, December 23rd.

Rockwell Medical Price Performance

RMTI stock opened at $2.23 on Friday. Rockwell Medical, Inc. has a 12 month low of $1.16 and a 12 month high of $5.15. The firm has a market capitalization of $72.07 million, a P/E ratio of -44.60 and a beta of 1.38. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. The firm has a 50 day moving average of $2.17 and a 200-day moving average of $2.75.

Rockwell Medical Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.